Dishman Carbogen soars 5% despite lacklustre Q4 earnings

The company posted a consolidated net profit of Rs72cr down by 5% in Q4 compared to Rs75.7cr a year ago same period.

Jun 04, 2020 04:06 IST India Infoline News Service

Dishman Pharmaceuticals
Dishman Carbogen Amcis witnessed a decline in both bottom-line and top-line front during March 2020 (Q4FY20) quarter. The company posted a  consolidated net profit of Rs72cr down by 5% in Q4 compared to Rs75.7cr a year ago same period.

Consolidated revenue from operations slumped by 17.8% to Rs502.8cr in the quarter against Rs611.4cr in the corresponding period of the previous year.

EBITDA meanwhile dropped by 22.1% to Rs131.8cr during the period against Rs169.3cr in Q4FY19. Whereas, EBITDA margins slipped to 25.8% in Q4 versus 26.1% in Q4FY19.

For FY20, the company recorded a net profit of Rs180.3cr down by 14.3% yoy, while the revenue stood at Rs1,919.9cr sequentially up by 2.8% yoy.

Post Q4, the company's stock ended at an upper price band of Rs73.55 per piece above 5% on Sensex during Thursday's trading session.

Related Story